Red Flags to Renal Rescue: Strengthening LN Care in Federal and FQHC Practice Environments

Lupus nephritis (LN) is one of the most consequential organ manifestations of systemic lupus erythematosus (SLE), occurring in approximately 40% to 60% of patients, most often within the first 5 years of diagnosis, and progressing to end-stage kidney disease in 10% to 20% of patients. LN is disproportionately concentrated in populations commonly cared for in federal, Veterans Affairs (VA), safety-net, and federally qualified health center (FQHC) practice environments, including Black, Hispanic, American Indian/Alaska Native, and Asian patients, as well as other patients with complex multimorbidity. Despite the availability of LN-specific U.S. Food and Drug Administration (FDA)-approved therapies, including belimumab, voclosporin, and obinutuzumab, as well as therapies approved for active extrarenal SLE manifestations, clinical practice continues to lag behind the evidence. The average time from SLE symptom onset to diagnosis is 6.29 years, and Black patients with SLE die approximately 13 years younger than their White counterparts; additionally, fewer than half of patients with active LN achieve a complete renal response at 1 year on conventional therapy. The 2024 American College of Rheumatology (ACR) Lupus Nephritis Guideline, the 2024 Kidney Disease: Improving Global Outcomes (KDIGO) guideline, and the 2025 European Alliance of Associations for Rheumatology (EULAR) recommendations for SLE with kidney involvement now converge on a practical care framework: routine surveillance for kidney involvement, early biopsy when LN is suspected, hydroxychloroquine (HCQ) at 5 mg/kg actual body weight when not contraindicated, glucocorticoid minimization, early use of combination immunosuppression, nephroprotective care, and treat-to-target monitoring using renal response criteria. In this CME Outfitters monograph, expert faculty will discuss recognizing early clinical and laboratory indicators of LN; implementing equitable guideline-concordant care that includes effective screening, referral, and patient-centered communication especially in underserved populations to support timely diagnosis; and integrating emerging LN therapies and clinical trial evidence into personalized, steroid-sparing treatment decisions and sequencing.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Pricing

Free

Reported to ACCME by the provider

On-demand / recorded video
includes Article / monograph / reference
Credit · Up to 1 credit
MOC · Up to 1 point
Commercial Support

Released

Jul 24, 2026
Last day to claim credit

Jul 25, 2027 10 months left

Red Flags to Renal Rescue: Strengthening LN Care in Federal and FQHC Practice Environments

Related courses

More from CME Outfitters, LLC